DealsThe world's largest drugmaker which raised 22

Any pain from those injured ribs numbed not only by a painkilling injection, but also the need to get on with the job.Any half-hearted concerns that Hasselbeck is a spent force were swiftly brushed aside with a dominant display.Chemistry seems to be building between quarterback and new receiver T.J. The first touchdown was a work of art and summed up the afternoon a wonderful pump fake deceiving Rashean Mathis and creating the perfect separation for Houshmandzadeh to score.He finished with 18 completions from 30 attempts, most of the incomplete passes being intelligent groundings under pressure.Take nothing away from a much improved defensive display. Lawrence Jackson continues to enjoy a productive start to his second season, recording his fourth sack. Aaron Curry again showed his limitless potential; whilst fellow rookie Nick Reed will never forget his 79-yard fumble return for a touchdown.But this one's on Hasselbeck.

Without him, the Seahawks are a shadow of the team they can be. We can stop looking now, because it's Matt Hasselbeck's arm.In 2007, he carried the team to 10-6, the NFC West title and the playoffs.He'll need to do it again.The running game is a mere compliment to what the focus has to be. Lose and you're season's over.The 41-0 score was a statement. It could be a shoot-out and once again Hasselbeck will need to be on top form to keep up with Kurt Warner, Larry Fitzgerald and co.If they can get to 3-3 before the bye, it's very much game on in the NFC West.But the Seahawks will only go as far as Hasselbeck can take them He proved that on Sunday.. NEW YORK (Reuters) - Pfizer Inc, the No 1 drugmaker, said on Monday that it would acquire U.S.

rival Wyeth for about $68 billion in a move to diversify its revenue base. DealsThe world's largest drugmaker, which raised $22.5 billion in debt from a consortium of banks to finance the deal, also cut its dividend.The following is reaction from industry analysts and investors:SEAMUS FERNANDEZ, ANALYST, LEERINK SWANN IN BOSTON"With Pfizer ideally suited to buy Wyeth in the current environment, we believe additional suitors are unlikely to emerge.""Although several companies may have the capability to execute a mega-merger in the current environment (JNJ, ABT, GSK, SNY), we believe that Pfizer is ideally suited to execute the deal due to limited overlap in its businesses and what we perceive to be reasonably aligned corporate cultures. We believe that Pfizer is best-positioned to deliver on the financing necessary to close the deal in the current environment."MICHAEL CASTOR, PORTFOLIO MANAGER, SIO CAPITAL MANAGEMENTIN NEW YORK"An acquisition of this nature can be valuable if management recognizes how rich their spending is and really cuts to maximize the profitability of the new organization $4 billion in cuts a good first step. There's a lot of potential to go deeper across the combined organization.""With the cost cuts that they've articulated, it's an OK deal, it's not destructive. But they could really make it into a good deal if they cut deeper, and I think there's the potential to do so."LES FUNTLEYDER, HEALTHCARE ANALYST, MILLER TABAK IN NEWYORK"Big mergers tend not to be value creators historically, maybe with the exception of Pfizer's Warner-Lambert deal to get Lipitor, and that is still is even an open question.""The odds do not favor necessarily the big merger working, but they had to do something. They had to buy time for their R&D units to kick out new drugs.""I think the market will be glad that Pfizer is actually doing something. They're cash rich so a combination of that has them in the market.I wouldn't extrapolate this deal and say we're going to see a lot more deals because it's still a difficult financing environment.Pfizer has a top tier balance sheet and they can handle something like this."ANDRE BAKHOS, PRESIDENT PRINCETON FINANCIAL GROUP, NEWBRUNSWICK, NEW JERSEY:"Deals of this quality and this magnitude will rekindle enthusiasm and hope about equity markets."In the midst of a global recession, here is Pfizer, hopefully spending their dollar's wisely."(Reporting by Ellis Mnyandu, Leah Schnurr and Lewis Krauskopf) Deals.